

13th International Conference on THROMBOSIS and HEMOSTASIS ISSUES in CANCER

April, 17 - 19, 2026

Centro Congressi Giovanni XXIII

Viale Papa Giovanni XXIII, 106 - Bergamo, Italy

Conference Chairmen

Anna Falanga
Benjamin Brenner
Alok A. Khorana

Chairman Emeritus

Frederick R. Rickles

Dear Colleagues,

We are pleased to invite you to ICTHIC, the high-level scientific conference dedicated to the critical interaction between thrombosis, hemostasis, and cancer.

Since its first edition in 2001, ICTHIC has provided an important forum to convene in the splendid medieval city of Bergamo, Italy. This biennial event, renowned for its elevated scientific quality and collaborative atmosphere, brings together the world's leading experts, researchers, clinicians, nurses and patients to explore the latest discoveries, current challenges, and prospects in this rapidly evolving field.

The connection between thrombosis and cancer has been recognized since the 19th century, but the field has seen significant growth in recent decades. Venous thromboembolism (VTE), a frequent complication in cancer patients, particularly during cancer treatment, negatively impacts the course and prognosis of malignant disease. Management is complex: these patients are more prone to thrombotic recurrences or bleeding complications during anticoagulant treatments, making it crucial to find an effective therapeutic balance.

ICTHIC aims to explore the most relevant aspects of coagulation derangement associated with cancer, from pathophysiological mechanisms to prevention, diagnosis, and treatment strategies.

The ultimate goal is to reduce the burden and consequences of cancer-associated thrombosis and hemorrhage, improve patient quality of life and management, and ease the burden on the healthcare system. ICTHIC explores the past, present, and future of this field, within a constantly evolving framework of research and medical progress.

The Conference Chairmen



Anna Falanga, MD



Benjamin Brenner, MD



Alok A. Khorana, MD

13th

International Conference on

THROMBOSIS & HEMOSTASIS ISSUES in CANCER

April, 17 - 19, 2026
Bergamo, Italy

Faculty

- Ageno, Walter - Italy
- Artoni, Andrea - Italy
- Ay, Cihan - Austria
- Becattini, Cecilia - Italy
- Bertolotti, Laurent - Italy
- Brenner, Benjamin - Israel
- Cannegieter, Suzanne - The Netherlands
- Carrier, Marc - Canada
- Castaman, Giancarlo - Italy
- Chalayer, Emilie - France
- Connors, Jean - US
- De Cristofaro, Raimondo - Italy
- De Stefano, Valerio - Italy
- Delluc, Aurelien - Canada
- Di Nisio, Marcello - Italy
- Dignat-George, Francoise - France
- Elalamy, Ismail - France
- Falanga, Anna - Italy
- Federici, Augusto Bramante - Italy
- Fowler, Matthew - UK
- Gervaso, Lorenzo - Italy
- Gerotziakas, Grigoris - France
- Giavazzi, Raffaella - Italy
- Grandone, Elvira - Italy
- Hamulyak, Eva - The Netherlands
- Hisada, Yohei - US
- Hoek-ten Cate, Arina - The Netherlands
- Iacoviello, Licia - Italy
- Kakkar, Ajay K. - UK
- Khorana, Alok A. - US
- Kirwan, Cliona - UK
- Klok, Erik F.A. - The Netherlands
- Kuderer, Nicole - US
- Lauw, Mandy - The Netherlands
- Leader, Avi - US
- Li, Ang - US
- Mahé, Isabelle - France
- Mantha, Simon - US
- Marchetti, Marina - Italy
- Martin, Karlyn - US
- Moik, Florian - Austria
- Muñoz Martin, Andrés J. - Spain
- Noble, Simon - UK
- O'Neill, Ann Marie - Ireland
- Pabinger, Ingrid - Austria
- Patrignani, Paola - Italy
- Pola, Roberto - Italy
- Prandoni, Paolo - Italy
- Rak, Janusz - Canada
- Sanfilippo, Kristen - US
- Schieppati, Francesca - Italy
- Simioni, Paolo - Italy
- Soria Fernández, José Manuel - Spain
- Spectre, Galia - Israel
- Spronk, Henri M.H. - The Netherlands
- Szmít, Sebastian - Poland
- ten Cate, Hugo - The Netherlands
- Tselepis, Alexandros - Greece
- Versteeg, Henri - The Netherlands
- Wang, Tzu-Fei - Canada
- Wells, Philip - Canada
- Zambelli, Alberto - Italy
- Zwicker, Jeffrey - US

13th

International Conference on

THROMBOSIS & HEMOSTASIS ISSUES in CANCER

April, 17 - 19, 2026
Bergamo, Italy

Local Organizing Committee

Anna Falanga
Marina Marchetti
Silvia Bolognini
Chiara Ticozzi

Chiara Ambaglio
Luca Barcella
Patricia Gomez-Rosas
Francesca Schieppati

Centro Emostasi e Trombosi, SIMT - ASST Papa Giovanni XXIII - Bergamo



Organizing Secretariat & Provider



Via Maestro Gaetano Capocci, 11
00199, Roma
tel. 342 0680078
segreteria@elleventi.it
www.elleventi.it

For updates, please visit www.ictic.com

13th

International Conference on THROMBOSIS & HEMOSTASIS ISSUES in CANCER

April, 17 - 19, 2026
Bergamo, Italy

In collaboration with:



With the auspices of:



UNIVERSITÀ
DEGLI STUDI
DI BERGAMO



Società Italiana di
Ematologia (SIE)



CASA DI CURA BEATO PALAZZOLO
BERGAMO



Fondazione
CARISMA
Casa di Ricovero
Santa Maria Ausiliatrice



Lectures and abstracts' publication

BLEEDING, THROMBOSIS AND VASCULAR BIOLOGY



Editor-in-Chief: Giovanni de Gaetano, Italy | eISSN: 2785-5309



FRIDAY, APRIL 17 th	09.00 Congress Opening	
	09.20 - 11.20 PLENARY SESSION 1 Cancer-Associated Thrombosis: From Risk to Diagnosis 11.00 Oral Communications ROOM OGGIONI - GROUND FLOOR	
	11.20 - 11.50 Coffee break DINING ROOM - GROUND FLOOR	
	11.50 - 13.30 PLENARY SESSION 2 Bleeding and Thrombosis in Hematological Malignancies 13.10 Oral Communications ROOM OGGIONI - GROUND FLOOR	
	13.45 - 14.30 Lunch Corporate Session ROOM ALABASTRO - 2ND FLOOR	
	15.00 - 16.40 PLENARY SESSION 3 Prevention and Treatment of CAT 16.20 Oral Communications ROOM OGGIONI - GROUND FLOOR	
	16.40 - 17.40 PLENARY LECTURE 9th Simon Karpatkin Memorial Lecture ROOM OGGIONI - GROUND FLOOR	

SATURDAY, APRIL 18 th	09.00 - 10.30 PLENARY SESSION 4 Bleeding, Microangiopathies, Thrombocytopenias: Challenging Conditions in Cancer 10.20 Oral Communications ROOM OGGIONI - GROUND FLOOR	
	10.30 - 10.50 Coffee break DINING ROOM - GROUND FLOOR	
	10.50 - 12.20 PLENARY SESSION 5 The Hemostasis-Cancer Crosstalk: Unraveling a Complex Interplay 12.20 Oral Communications ROOM OGGIONI - GROUND FLOOR	
	12.30 - 12.45 Lunch Break ROOMS: STUCCHI, ALABASTRO A, ALABASTRO B, NOVELLI	
	12.45 - 15.25 Poster Discussion Sessions ROOMS: STUCCHI, ALABASTRO A, ALABASTRO B, NOVELLI 1ST and 2ND FLOOR	
	15.30 - 17.00 PLENARY SESSION 6 Addressing Complex Hemostatic Challenges in Oncology 16.50 Oral Communications ROOM OGGIONI - GROUND FLOOR	
	17.00 - 17.30 SPECIAL SESSION One Aspirin Per Day Keeps Cancer Away? Aspirin's Promise in Cancer Prevention	

SUNDAY, APRIL 19 th	08.45 - 10.15 A MULTIDISCIPLINARY ROUND TABLE Discussion on Implementing Strategies for CAT Prevention ROOM OGGIONI - GROUND FLOOR	
	10.15 - 10.45 Coffee break DINING ROOM - GROUND FLOOR	
	10.45 - 12.25 PLENARY SESSION 7 Advances in Predicting Cancer-Associated Thrombosis and Bleeding 12.05 Oral Communications ROOM OGGIONI - GROUND FLOOR	
	12.30 - 14.00 Lunch Break DINING ROOM - GROUND FLOOR	
	14.00 - 15.40 PLENARY SESSION 8 Beyond One-Size-Fits-All: Personalized Thromboprophylaxis in CAT	
	15.40 - 15.50 CONCLUDING REMARKS ROOM OGGIONI - GROUND FLOOR	

13th

International Conference on

THROMBOSIS & HEMOSTASIS ISSUES in CANCER

April, 17 - 19, 2026
Bergamo, Italy

Friday, April 17th

09:00 - 09:20

Congress opening

Opening remarks from the Conference Chairmen

Anna Falanga (Italy), Benjamin Brenner (Israel), Alok A.Khorana (US)

09:20 - 11:20

PLENARY SESSION 1

Cancer-associated thrombosis: From Risk to Diagnosis

Chairs: Anna Falanga (Italy), Alok A. Khorana (US)

09:20 - 09:40

Current Trends in Cancer-Related Thrombosis: Insights in Epidemiology and Risk Factors

Suzanne Cannegieter (The Netherlands)

09:40 - 10:00

Facts and Figures in Occult Cancer Screening Among Patients with Unprovoked VTE

Aurelien Delluc (Canada)

10:00 - 10:20

The Unrecognized Threat: Isolated Superficial Venous Thrombosis in Cancer

Philip Wells (Canada)

10:20 - 10:40

Reforming Thrombotic Event Reporting in Cancer Clinical Trials: A Path to Better Data

Nicole Kuderer (US)

10:40 - 11:00

Natural Language Processing Model for Cancer-Associated Thrombosis

Ang Li (US)

11:00 - 11:10

Selected Abstracts

OC01 Incidence and Risk of Cancer After Incident Venous Thromboembolism or Cerebral Vein Thrombosis: Evidence From Administrative Healthcare Databases

Luisa Ojeda Fernandez (Italy)

11:10 - 11:20

OC02 Incidence and predictors of arterial thrombosis in cancer patients: results from the prospective COMPASS-Arterial Cancer Associated Thrombosis (COMPASS-ARTeCAT) Study

Grigorios Gerotziakas (France)

11:20 - 11:50

Coffee break



13th

International Conference on

THROMBOSIS & HEMOSTASIS ISSUES in CANCER

April, 17 - 19, 2026
Bergamo, Italy

Friday, April 17th

11:50 - 13:30

PLENARY SESSION 2

Joint Session with EHA-SWG

Bleeding and Thrombosis in Hematological Malignancies

Chairs: Giancarlo Castaman (Italy), Cihan Ay (Austria)

11:50 - 12:10

Navigating the Dual Challenge of Acute Promyelocytic Leukemia: Unraveling Hemorrhagic Risk in an Era of Favorable Prognosis

Yohei Hisada (US)

12:10 - 12:30

Thromboprophylaxis in Acute Lymphoblastic Leukemia

Mandy Lauw (The Netherlands)

12:30 - 12:50

**Optimizing Anticoagulation in Multiple Myeloma:
A consensus Statement from an Expert panel**

Valerio De Stefano (Italy)

12:50 - 13:10

The CAR-T Coagulopathy

Avi Leader (US)

Selected Abstracts

13:10 - 13:20

OC03 Thromboembolic Prevalence in Multiple Myeloma Before and After the Introduction of Direct Oral Anticoagulants: A Longitudinal Cohort Study

Alexandra Sánchez (Mexico)

13:20 - 13:30

OC04 Direct oral anticoagulants provide effective thromboprophylaxis in newly diagnosed myeloma: Real world findings from the ATOMM Study

Marquita Camilleri (UK)

13:45 - 14:30

Lunch Corporate Session (see page 22)

15:00 - 16:40

PLENARY SESSION 3

Prevention and Treatment of CAT

Chairs: Cliona C. Kirwan (UK), Paolo Prandoni (Italy)

15:00 - 15:20

**Anticoagulation for Cancer-Associated Thrombosis:
Defining the Optimal Duration**

Isabelle Mahé (France)



13th

International Conference on

THROMBOSIS & HEMOSTASIS ISSUES in CANCER

April, 17 - 19, 2026
Bergamo, Italy

Friday, April 17th

15:20 - 15:40

Extended Postoperative Thromboprophylaxis in Cancer Surgery: Evidence, Guidelines, and Future Directions

Ajay K. Kakkar (UK)

15:40 - 16:00

The Therapeutic Landscape of Cancer-Associated Splanchnic Vein Thrombosis

Walter Ageno (Italy)

16:00 - 16:20

Atrial Fibrillation in Cancer: Balancing Anticoagulation and Oncologic Treatment

Sebastian Szmit (Poland)

16:20 - 16:30

Selected Abstracts

OC05 Time to start of anticoagulant therapy and survival outcomes in cancer patients with pulmonary embolism

Kristen Sanfilippo (US)

16:30 - 16:40

OC06 Primary thromboprophylaxis (PTP) in advanced pancreatic ductal adenocarcinoma (aPDAC) undergoing systemic anticancer treatment (SACT): A cancer-centre cohort study on clinical practice and outcomes

Farzana Haque (UK)

16:40 - 17:40

PLENARY LECTURE

9th Simon Karpatkin Memorial Lecture

Chairs: Anna Falanga (Italy), Benjamin Brenner (Israel), Alok A. Khorana (US)

The Thrombo-Inflammatory Landscape of Cancer Associated Thrombosis

Jeffrey Zwicker (US)

17:40 - 19:00

Welcome Reception



13th

International Conference on

THROMBOSIS & HEMOSTASIS ISSUES in CANCER

April, 17 - 19, 2026
Bergamo, Italy

Saturday, April 18th

09:00 - 10:30

PLENARY SESSION 4

Bleeding, Microangiopathies, Thrombocytopenias: Challenging Conditions in Cancer

Chairs: Benjamin Brenner (Israel), Marina Marchetti (Italy)

09:00 - 09:20

Bleeding in Cancer: Epidemiological Aspects

Kristen Sanfilippo (US)

09:20 - 09:40

Anticoagulation Challenges in Thrombocytopenic Cancer Patients

Emilie Chalayer (France)

09:40 - 10:00

Cancer-Related Microangiopathies: Leveraging the Thrombotic Thrombocytopenic Purpura Model for Therapeutic Innovation

Francesca Schieppati (Italy)

10:00 - 10:20

Mortality Following Major Gastrointestinal Bleeding Among Patients Receiving DOACs

Marc Carrier (Canada)

10:20 - 10:30

Selected Abstracts

OC07 Assessment of bleeding in patients with chemotherapy induced thrombocytopenia treated with romiplostim

Cy R. Wilkins (US)

10:30 - 10:50

Coffee break

10:50 - 12:20

PLENARY SESSION 5

The Hemostasis-Cancer Crosstalk: Unraveling a Complex Interplay

Chairs: Françoise Dignat-George (France), Galia Spectre (Israel)

10:50 - 11:10

Modeling Cancer-Associated Thrombosis: The Promise of Organ-on-a-Chip Technology

Henri Versteeg (The Netherlands)

11:10 - 11:30

Factor XI Inhibitors in CAT: What's Next?

Alok A. Khorana (US)



Saturday, April 18th

- 11:30 - 11:50 **Mechanistic Insights into Cancer-Associated Thrombosis in Brain Cancer**
Janusz Rak (Canada)
- Selected Abstracts**
- 11:50 - 12:00 **OC08 A silk-based 3D bone marrow model for chemotherapy-induced thrombocytopenia**
Alessandra Balduini (Italy)
- 12:00 - 12:10 **OC09 Bleeding risk associated with factor XI (FXI) monoclonal antibodies in combination with aspirin (ASA) in healthy volunteers and orthopedic surgery patients: analysis from recent Phase1 and Phase 2 studies**
Aaron P. Kithcart (US)
- 12:10 - 12:20 **OC10 From design to clinical phase 3 in oncology: CD13-targeted tissue factor tTF-NGR and tumor infarction**
Wolfgang E. Berdel (Germany)
- 12:30 - 12:45 **Lunch break** in the poster discussion rooms
- 12:45 - 15:25 **POSTER DISCUSSION SESSIONS** (see page 10)
- 15:30 - 17:00 **PLENARY SESSION 6**
Addressing Complex Hemostatic Challenges in Oncology
Chairs: Augusto Bramante Federici (Italy), Ingrid Pabinger (Austria)
- 15:30 - 15:50 **Diagnosis and Management of Acquired Bleeding Disorders in Cancer**
Raimondo De Cristofaro (Italy)
- 15:50 - 16:10 **Outpatient Management of Pulmonary Embolism in cancer patients**
Laurent Bertoletti (France)

13th

International Conference on

THROMBOSIS & HEMOSTASIS ISSUES in CANCER

April, 17 - 19, 2026
Bergamo, Italy

Saturday, April 18th

- 16:10 - 16:30 **Pharmacokinetic Interactions Between Antitumor Drugs and DOACs: Clinical Implications for Safe Anticoagulation**
Tzu-Fei Wang (Canada)
- 16:30 - 16:50 **Antithrombotic Therapy in Palliative Cancer Care: Balancing Bleeding and Thrombotic Risk**
Simon Noble (UK)
- 16:50 - 17:00 **Selected Abstracts**
OC11 Complexities in managing antithrombotic therapy in patients with cancer approaching end-of-life: a mixed method integration using joint display analysis
Elin Baddeley (UK)
- 17:00 - 17:30 **SPECIAL SESSION**
Chair: Henri M.H. Spronk (The Netherlands)
One Aspirin Per Day Keeps Cancer Away? Aspirin's Promise in Cancer Prevention
Paola Patrignani (Italy)
- Discussant: Alexandros Tselepis (Greece)**



13th

International Conference on

THROMBOSIS & HEMOSTASIS ISSUES in CANCER

April, 17 - 19, 2026
Bergamo, Italy

Sunday, April 19th

08:45 - 10:15

ROUND TABLE

Joint session with ARTET Foundation for research on thrombosis and hemostasis in cancer

A Multidisciplinary Round Table Discussion on Implementing Strategies for CAT Prevention

Introduction: Raffaella Giavazzi (Italy)

Chairs: Alberto Zambelli (Italy), Roberto Pola (Italy)

08:45 - 09:00

Understanding the Landscape - Perspectives on CAT Prevention Needs

Grigorios Gerotziakas (France)

09:00 - 09:15

The role of the Oncologist

Lorenzo Gervaso (Italy)

09:15 - 09:30

Designing Comprehensive and Impactful Implementation Strategies for CAT prevention

Karlyn Martin (US)

09:30 - 09:45

The VTE Communication Toolkit: Facilitating Effective Management Across the Care Team

F.A. Erik Klok (The Netherlands)

09:45 - 10:15

Discussants:

Matthew Fowler (UK, nurses' representative),

Ann Marie O'Neill (Ireland, patients' representative)

10:15 - 10:45

Coffee break



13th

International Conference on

THROMBOSIS & HEMOSTASIS ISSUES in CANCER

April, 17 - 19, 2026
Bergamo, Italy

Sunday, April 19th

10:45 - 12:25

PLENARY SESSION 7

Advances in Predicting Cancer-Associated Thrombosis and Bleeding

Chairs: Andrés J. Muñoz Martín (Spain), Licia Iacoviello (Italy)

10:45 - 11:05

**Next-Generation Biomarkers for CAT Prediction:
The Role of Non-Genomic-Omics**

José Manuel Soria Fernández (Spain)

11:05 - 11:25

**Prediction and management of recurrent venous
thromboembolism in patients with cancer**

Marcello Di Nisio (Italy)

11:25 - 11:45

**Predicting Anticoagulant-Related Bleeding in Cancer-
Associated Thrombosis: Risk Factors and Models**

Cecilia Becattini (Italy)

11:45 - 12:05

**Genomic Profiling for Thrombosis Risk Prediction in
Myeloproliferative Neoplasms**

Simon Mantha (US)

12:05 - 12:15

Selected Abstracts

**OC12 Risk of venous thromboembolism after removal of an upper
extremity central catheter associated with a deep vein thrombosis
in cancer patients**

Michelangelo Sartori (Italy)

12:15 - 12:25

**OC13 Von Willebrand Factor predicts poor outcome in pancreatic
cancer and mediates tumor-endothelium interactions facilitating
metastasis**

Betül Ünlü (Ireland)

12:30 - 14:00

Lunch break



13th

International Conference on

THROMBOSIS & HEMOSTASIS ISSUES in CANCER

April, 17 - 19, 2026
Bergamo, Italy

Sunday, April 19th

14:00 - 15:40

PLENARY SESSION 8

Beyond One-Size-Fits-All:

Personalized Thromboprophylaxis in CAT

Chairs: Ismail Elalamy (France), Arina J. Hoek ten Cate (The Netherlands)

14:00 - 14:20

Unlocking the Potential of Statins for VTE Prophylaxis in Cancer

Jean Connors (US)

14:20 - 14:40

Thromboprophylaxis in Intracranial Tumors

Eva Hamulyak (The Netherlands)

14:40 - 15:00

Optimizing Thromboprophylaxis in Pediatric Cancer Patients: Dosing and Management Challenges

Paolo Simioni (Italy)

15:00 - 15:20

Anticoagulation During anti-VEGF therapy

Florian Moik (Austria)

15:20 - 15:40

Hormones, Cancer, and Thrombosis with a Special Focus on Sex Differences

Elvira Grandone (Italy)

15:40 - 15:50

Concluding Remarks

Anna Falanga (Italy), Benjamin Brenner (Israel), Alok A. Khorana (US)



Poster Discussion - Session I

Room Alabastro A

Basic Science, Tumor Microenvironment, Novel Mechanisms

Chair: Grigorios Gerotziafas (France)

- PO01 Melanoma-Derived Extracellular Vesicles Drive von Willebrand Factor-Dependent Thrombosis and Metastasis**
Y. Wang, X. Liu, T. Downar, A. Topuz, A. Bauer, J. Kött, K. Nekipelov, S. Brenna, G. Bendas, B. Puig, S. Schneider, D. Fedosov, C. Gorzelanny
- PO02 Synergistic Interaction of Endothelial and Cancer Cells in the Formation and Structure of the Fibrin Clot Shields**
M. A. Baghdadi, E. Mbemba, P. Las Casa, P. Van Dreden, N. Saleem, J. Fareed, P. Kempaiah, M. Sabbah, G. Gerotziafas
- PO03 Hepatic fibrosis-driven tissue factor expression by malignant cholangiocytes is associated with cancer-associated thrombosis and poor survival in intrahepatic cholangiocarcinoma**
L. Fabris, Y. Frión-Herrera, C. Venturin, M. Cadamuro, J. Gasparello, C. M. Radu, M. Fassan, C. Mescoli, U. Cillo, E. Gringeri, G. Zanús, E. Campello, M. Strazzabosco, P. Simioni
- PO04 Fibrin clot shields promote clonal selection in cancer cells: procoagulant activity and survival of clot-embedded cells: a novel tumor microenvironment model**
M. A. Baghdadi, E. Mbemba, P. Las Casa, P. Van Dreden, N. Saleem, J. Fareed, P. Kempaiah, M. Sabbah, G. Gerotziafas
- PO05 Design, synthesis, and biological evaluation of novel imatinib and nilotinib analogues expressing enhanced antiplatelet and anticancer activities**
D. Pantazi, L. Pechlivani, A. Kosma, K. Lalechou, M. G. Siskos, D. Alivertis, A. D. Tselepis
- PO06 Activated Platelets Induce The Formation Of Neutrophil Extracellular Traps Via Toll-Like Receptor-4 And P-selectin Glycoprotein Ligand-1**
I. C. Moschonas, A. D. Tselepis

PO07 Platelet inhibition by the novel nitric oxide-donor Nitrosooxypropanol (PDNO)

M. Lindkvist, J. Jakobsson, F. Lynfeldt, B. Sandberg, K. Fransén, K. Nilsson, M. Grenegård

PO08 Next-generation thrombolytics: engineering streptokinase for enhanced activity and reduced immunogenicity

M. Kanwal

12:45 – 14:00

Poster Discussion - Session II

Room Alabastro B

Epidemiology, Big Data, Population Studies

Chair: Hugo ten Cate (The Netherlands)

PO09 Cancer mortality after incident venous thromboembolism

C. Langholm, N. H. Eide, K. Hveem, N. Van Es, V. M. Morelli, S. K. Braekkan, J. B. Hansen

PO10 Risk of venous thromboembolism in cancer patients with central venous catheters: results from the Vienna CAT-BLED study

B. Sunder-Plassmann, N. Vladic, C. Englisch, F. Moik, V. Sunder-Plassmann, A. Berghoff, M. Preusser, I. Pabinger, C. Ay

PO11 Thromboembolic events during perioperative therapy for resectable and borderline resectable pancreatic cancer in the PREOPANC-2 trial

R. A. L. Willems, A. E. Van Diepen, E. N. Dekker, Q. P. Janssen, J. L. Van Dam, N. Michiels, C. W. F. Van Eijck, K. E. P. E. Hermans, B. A. Bonsing, K. P. Bosscha, S. A. W. Bouwense, O. R. Busch, H. Ten Cate, P. P. L. O. Coene, C. H. J. Van Eijck, N. Van Es, E. Van Der Harst, I. H. J. T. De Hingh, T. M. Karsten, G. Kazemier, M. B. Van Der Kolk, B. De Laat, M. S. L. Liem, J. S. D. Mieog, V. B. Nieuwenhuijs, G. A. Patijn, M. Roest, H. C. Van Santvoort, L. Valkenburg-Van Iersel, R. F. De Wilde, F. Wit, B. M. Zonderhuis, M. G. Besselink, M. Y. V. Homs, G. Van Tienhoven, J. W. Wilmink, B. Groot Koerkamp, Judith De Vos-Geelen

PO12 Impact of inherited thrombophilia on cancer-associated thrombosis: a systematic review and meta-analysis

E. Campello, G. Furlan, A. Boccataonda, A. Napolitano, C. Simion, P. Simioni

- PO13 Outpatient treatment of venous thromboembolism and subsequent risk of cancer**
S. Sørensen, D. Farkas, H. Sørensen
- PO14 Symptom burden in patients with cancer and thromboembolism: a population-based matched cohort study**
D. Siegal, Z. O'Neill, L. Nguyen, N. Liu, M. Carrier, R. Sutradhar
- PO15 Venous Thromboembolism and 20-Year Cancer Risk: A Danish Population-Based Cohort Study**
S. K. Martiny, V. Lanting, D. K. Farkas, N. Van Es, H. T. Sørensen
- PO16 Epidemiology, clinical characteristics, and outcomes of provoked and unprovoked pulmonary embolism in a multicultural Israeli population**
R. Farah, N. L. Bragazzi, H. İ. Ceylan, Ł. Szarpak, W. Mahajni, N. Ashqar, A. M. Fioretti, R. Khamisy-Farah

12:45 – 14:00

Poster Discussion - Session III

Room Novelli

Immunothrombosis, Inflammation, CAR-T

Chair: Andrea Artoni (Italy)

- PO17 Predictive value of inflammatory and endothelial biomarkers for cancer risk in healthy individuals: evidence from the HYPERCAN study**
C. Ticozzi, S. Bolognini, P. Gomez-Rosas, F. Schieppati, G. Sampietro, L. Barcella, M. Marchetti, A. Falanga
- PO18 The thrombo-inflammation axis as predictor of toxicity in patients treated with CAR-T cells**
C. Fernández-Arias, M. Marcos-Jubilar, M. Panizo, C. Vázquez-Puerta, J. R. González-Porras, M. Ibáñez, A. Queral, M. Carrasco, M. B. Villacrés, C. Conde, P. Elizalde, S. Huerga, A. Alfonso, P. Rodríguez-Otero, S. Villar, M. A. Canales, J. Rifón, F. Prósper, J. A. Páramo, J. Orbe, R. Lecumberri

- PO19 The Interrelationship between NETosis, the ADAMTS-13/VWF Axis, and Hemostatic Activation in Patients with Gynecological Malignancies: Prognostic Significance and Impact of Chemotherapy**
A. Makatsariya, B. Ekaterina, V. Bitsadze, J. Khizroeva, A. Vorobev, A. Solopova, M. Tretyakova, N. Gashimova, K. Grigoreva, O. Arina, J. C. Gris, I. Elalamy, G. Gerotziafas
- PO20 Dysfunction of the ADAMTS-13 / von Willebrand Factor Axis, Mediated by NETosis, as a Driver of Prothrombotic State and Unfavorable Prognosis in Oncogynecological Patients**
V. Bitsadze, B. Ekaterina, J. Khizroeva, A. Solopova, M. Tretyakova, N. Gashimova, K. Grigoreva, Alena Tatarintseva, J. C. Gris, I. Elalamy, G. Gerotziafas, A. Makatsariya
- PO21 Psychological Impact of Cancer-Associated Thrombosis: Dual burden and Implications for Quality of Life and Integrated Patient-Centered Care**
G. Gerotziafas, Y. Mitrou, M. Marchetti, P. Las Casa, A. Tafur, V. Bitsadze, J. Khizroeva, D. Taizhanova, D. Antic, C. Frère, A. Makatsariya, L. Garderet, A. Escargueil, C. Ay, N. Lomatkin, Z. Tazi-Mezalek, M. Sassi, M. Catalano, J. Gligorov, J. Caprini, P. Van Dreden, J. Fareed, A. Falanga
- PO22 Long-Term Anticoagulant Therapy and Reduction of Ovarian Cancer Recurrence: Clinical Evidence of a Potential Antitumour Effect**
J. Khizroeva, V. Bitsadze, A. Vorobev, A. Solopova, M. Tretyakova, N. Gashimova, K. Grigoreva, A. Khisamieva, J. Gris, I. Elalamy, G. Gerotziafas, A. Makatsariya
- PO23 Immune thrombotic thrombocytopenic purpura related to delayed immune checkpoint inhibitors toxicity: a case report**
E. Galimberti, F. Schieppati, C. Ambaglio, M. Marchetti, L. Barcella, A. Falanga
- PO24 We are juggling many possibilities: Healthcare professionals' experiences and perspectives on interpretation of pulmonary embolism signs and symptoms in patients with lung cancer**
Aa. Højen, M. Søgaaard, Ag. Ording, Mr Saugbjerg, Td. Christensen, Hr. Jacobsen, L. Jørgensen, H. Enggaard

Poster Discussion - Session IV

Room Stucchi

Anticoagulant Therapy, DOACs, Clinical Management

Chair: Ingrid Pabinger (Austria)

- PO25 Evolution of Anticoagulant Strategies and Clinical Outcomes in Cancer-Associated Thrombosis: A Longitudinal Analysis of the START2 Registry ONCO-VTE**
M. Marchetti, T. Zollner, O. C. Cretu, A. Chistolini, R. Pancani, L. Puccetti, P. Sivera, W. Ageno, G. Elmi, V. Fregoni, V. Tonelli, E. Antonucci, D. Poli, A. Falanga, L. Barcella
- PO26 Outcomes of Direct Oral Anticoagulants in Unusual-Site Thrombosis: Impact of Active Cancer**
S. Guglielmo, M. Lovisotto, L. Scarano, E. De Bon, S. Barbar
- PO27 Urine qualitative assessment of direct oral anticoagulants (DOACs) in routine clinical practice**
F. Schieppati, P. Gomez-Rosas, C. Ambaglio, V. Brusegan, O. C. Cretu, E. Galimberti, F. Zunino, L. Barcella, J. Harenberg, A. Falanga, M. Marchetti
- PO28 Clinical Implications of Anticoagulant Drug Interactions with Targeted and Immune Therapies in Oncology: A Contemporary Risk Stratification Framework**
D. Dhami, C. Solowiej Singh, M. Dhami
- PO29 Canadian insights into the management of breakthrough thrombosis**
S. Ramdani, C. Séguin
- PO30 Long-Term Anticoagulant Therapy and Prevention of Recurrent Venous Thromboembolism in Advanced Ovarian Cancer**
V. Bitsadze, A. Vorobev, J. Khizroeva, A. Solopova, M. Tretyakova, N. Gashimova, Kristina Grigoreva, A. Khisamieva, J. Gris, I. Elalamy, G. Gerotziafas, A. Makatsariya
- PO31 Migratory Superficial Thrombophlebitis Refractory to Apixaban in a Patient with Lung Adenocarcinoma**
I. Goldberg, P. Raanani, G. Spectre
- PO32 Anticoagulant thromboprophylaxis in aggressive Lymphomas patients: predictive thrombotic risk scores and risk factors**
L. Gurgoglione, G. Gini, S. Rupoli, A. Poloni

PO33 Variation in Comorbidity Burden and Sex Distribution Across Causes of Death in Cancer at a Single Institution

D. Cicka, K. Bria, S. Xiong, F. Boghani, R. Dingle, C. Dong, K. Sanfilippo

14:10 – 15:25

Poster Discussion - Session V

Room Alabastro A

**Clinical Research, Real-World Data,
Catheter Complications**

Chair: Paolo Prandoni (Italy)

PO34 Investigators' Decisions on Anticoagulation after Extended API-CAT Treatment for Cancer VTE

I. Mahé, F. Happe, M. Monreal, H. Robert-Ebadi, P. Debourdeau, J. R. Fabreguettes, S. Accassat, P. Mismetti, P. Girard, S. Laporte, C. Chapelle

PO35 A multicentre audit of current tumour thrombosis management in the United Kingdom

A. Bhatti, L. Tafesh, A. Waton, M. Thomas, N. Prasannan, A. Bhide, R. Walsh, T. Lucas, K. White, T. Bariana, O. Tsiamita, S. Soman, P. Woolley, I. Lacey, K. Musgrave

PO36 Extended duration reduced dose anticoagulation in cancer-associated thrombosis (CAT): a real-world cohort with long term follow up

A. Bhide, I. Welding, O. Ogunbiyi, S. Hawkins, E. Greenlay, N. Prasannan, J. Westwood, M. Thomas

PO37 Clinical significance of symptomatic and incidental venous thromboembolism in cancer patients treated with apixaban

P. Hussaini, T. L. Larsen, W. Ghanima, A. E. A. Dahm

PO38 Pericatheter and systemic thrombosis during CAR-T lymphocytapheresis: incidence and clinical correlates

I. Pansini, E. Galli, A. Corrente, N. Piccirillo, M. Viscovo, S. Hohaus, P. Chiusolo, F. Sorà, S. Sica

PO39 Risk of Venous Thromboembolism Associated With Peripherally Inserted Central Catheters in Cancer Patients Receiving Chemotherapy: A Real-World Single-Centre Experience

S. Gilani, H. Rubbani, A. Mackie

- PO40** **RADAR, UK-MRA Myeloma XV - Comparing MRD-Guided Treatment Escalation and De-Escalation Strategies in Patients with Newly Diagnosed Myeloma Suitable for Stem Cell Transplantation: Thromboprophylaxis subgroup study protocol**
Z. Sayar On Behalf Of The Radar Investigators
- PO41** **Venous thromboembolism in peripheral blood stem cell collection - a single center experience**
P. Holly, J. Hudecek, J. Chudej, L. Valekova, I. Plamenova, E. Flochova, R. Simonova, J. Sokol, J. Stasko, M. Pietrzykova, E. Vescecikova

14:10 – 15:25

Poster Discussion - Session VI

Room Alabastro B

Biomarkers, Genomics, Precision Medicine

Chair: Marina Marchetti (Italy)

- PO42** **Differential expression of Hemostatic Biomarkers across Cancer Type and Disease stage: A Prospective Analysis of 4,292 patients from the HYPERCAN study**
P. Gómez-Rosas, D. Romeo, S. Bolognini, C. Ticozzi, F. Schieppati, A. D'alessio, R. Labianca, A. Falanga, M. Marchetti On Behalf Of The Hypercan Investigators
- PO43** **Elevated circulating tissue plasminogen activator (tPA) levels predict gastrointestinal and breast cancer risk: a prospective nested case-cohort study**
S. Bolognini, C. Ticozzi, P. Gomez-Rosas, F. Schieppati, G. Sampietro, L. Barcella, M. Marchetti, A. Falanga
- PO44** **Predictors of One-Year Mortality in Newly Diagnosed Metastatic Breast Cancer: The Prognostic Role of Hemostatic Biomarkers and Early Thromboembolism**
M. Marchetti, P. Gomez-Rosas, S. Bolognini, C. Ticozzi, D. Romeo , F. Schieppati, L. Barcella, F. Petrelli, A. D'alessio, R. Labianca, A. Falanga On Behalf Of The Hypercan Investigators

- PO45 Khorana risk score and genomic profiling for prediction of venous thromboembolism in ovarian cancer**
P. Santini, L. Mastrantonio, G. Anderson, F. Camarda, I. Marino, J. Preziosi, M. Buttarelli, M. Manfredelli, A. Minucci, F. Persiani, L. Giacò, T. Pasciuto, I. Conti, I. Mozzetta, F. Mancinetti, S. M. P. D'ambrosio, M. Bigossi, C. Marchetti, V. Salutati, G. Scambia, C. Nero, R. Pola
- PO46 Transcriptomic profiling of plasma extracellular vesicles reveals a candidate immuno-thrombotic mRNA signature for cancer-associated thrombosis in lung adenocarcinoma**
M. Marcos-Jubilar, C. Fernandez-Arias, C. Herrero, E. Guruceaga, K. Valencia, P. Elizalde, S. Inoges, R. Lecumberri, J. Orbe
- PO47 Venous Thromboembolism in Breast Cancer: Insights from a Single-Center Cohort**
S. Kozhukhov, N. Dovganych
- PO48 Breast Cancer is Associated with High Plasminogen Activator Inhibitor-1 and Impaired Fibrinolysis**
L. Macdonald, R. Moir, A. Strachan, M. Piana, J. Smith, C. James, J. Innes, S. Murdoch, J. Wilson, S. Richardson, N. J. Mutch, V. Speirs, B. Elsberger, C. S. Whyte
- PO49 Prophylactic anticoagulation decisions in high-risk patients receiving cancer-directed therapy: analysis of the Vermont Method**
J. Barker, K. Libby, C. Holmes, K. Martin

14:10 – 15:25

Poster Discussion - Session VII

Room Novelli

Novel Anticoagulants, FXI Inhibitors, Risk Assessment

Chair: Cihan Ay (Austria)

- PO50 Sub-analysis of interim results from a Phase 2 study investigating REGN9933^{A2} and REGN7508^{CAT} for the prevention of contact-mediated venous thromboembolism (VTE) in patients with active cancer undergoing peripherally inserted central catheter (PICC) placement (ROXI-CATH)**
J. Zwicker, A. P. Kithcart, J. Kaplan, Y. -C. Cheng, J. G. Raya, J. Xiao, S. Li, K. Musgrave, D. E. Gutstein, G. Piazza

- PO51 Mechanistic population pharmacokinetic/pharmacodynamic modeling of factor XI-targeting monoclonal antibodies supports durable anticoagulant coverage and translational dose and regimen selection**
O. Milberg, H. Abdallah, R. K. Lokken, R. Dingman, K. A. Meagher, M. E. Burczynski, E. Marin, A. P. Kithcart, D. E. Gutstein
- PO52 Mechanistic population pharmacokinetic/pharmacodynamic and time-to-event modeling support sustained Factor XI inhibition and superior post-operative venous thromboembolism prevention with REGN7508^{CAT}**
O. Milberg, H. Abdallah, R. K. Lokken, R. Dingman, K. A. Meagher, P. Banerjee, M. E. Burczynski, E. Marin, A. P. Kithcart, D.E. Gutstein
- PO53 Phase 3 trial evaluating the efficacy and safety of REGN7508^{CAT} for primary prophylaxis of cancer-associated thrombosis for participants with solid tumors undergoing cancer treatment (ROXI-CAT-I)**
J. Zwicker, M. P. O'Brien, M. Carrier, J. Connors, A. Falanga, A. Manzano, R. Mcbane, Y. Y. Janjigian, G. O'kane, M. Onisko, J. Kaplan, A. P. Kithcart, D. E. Gutstein, A. Khorana, M. F. Walsh
- PO54 Cancer-associated thrombosis in aspirin-treated patients after arterial thrombosis: The COMPASS-ARTECAT-ASA Prospective Cohort Study**
S. Allakhverdieva, P. Henrique Fernandes Do Carmo Las Casa, P. Van Dreden, J. Fareed, G. Gerotziakas, N. Lomakin, I. Zotova, L. Buryachkovskaya
- PO55 History of cancer in patients with severe hereditary thrombophilia versus no thrombophilia: a single-center cohort of patients with venous thrombosis**
A. Napolitano, E. Campello, C. Simion, G. Furlan, S. Gavasso, C. Bulato, C. Samà, S. Toffanin, B. Serena, L. Spiezia, P. Simioni
- PO56 External Validation of the SAVED Score in a Canadian Regional Cancer Centre Cohort: A Real-World Analysis**
A. Naassan, R. Fatima, M. Naassan, C. Chisholm
- PO57 A novel risk assessment model for cancer detection within one year after incident venous thromboembolism (VTE)**
C. Antoun, J. Hansen, S. Brækkan, C. Langholm, N. Eide, V. Morelli, K. Hveem
- PO58 Tackling the awareness gap in cancer-associated thrombosis: Impact of a brief educational intervention in patients with gynecological cancers**
P. Santini, F. Mancinetti, G. Fracassa, E. Fondi, E. Ianuà, A. D'errico, M. Bigossi, C. Marchetti, V. Salutati, G. Scambia, C. Nero, R. Pola

14:10 – 15:25

Poster Discussion - Session VIII

Room Stucchi

Special Populations, Hematologic Malignancies, Bleeding

Chair: Avi Leader (US)

- PO59 Platelet Aggregation and Thrombin Generation in Multiple Myeloma: A Prospective Study**
M. Biglietto, R. Mormile, A. Piciocchi, F. Fazio, M. Capriata, S. Sorella, B. Mandelli, D. Kasmi, E. Baldacci, A. Chistolini, M. T. Petrucci, C. Santoro
- PO60 VEXAS syndrome as a new severe thrombophilic clonal condition: a single centre experience**
C. Ambaglio, E. Galimberti, F. Schieppati, M. Frigeni, M. Marchetti, L. Barcella, A. Falanga
- PO61 Risk Factors for Intracranial Haemorrhage: An Umbrella Review to Inform Machine Learning Prediction Models in Glioma Patients Receiving Anticoagulation**
T. Adeyemo, S. Greenley, F. Ware, W. Jones, A. Maraveyas, F. Haque
- PO62 Clinical and Molecular Diagnostic Challenges in Myeloproliferative Neoplasms With Low JAK2V617F Allelic Burden**
E. Morsia, D. Lame, M. Pianelli, G. Gramazio, R. Ceccarelli, I. Battilà, S. Rupoli, A. Poloni
- PO63 Extended Anticoagulation with DOACs in patients affected by hematologic malignancies and venous thromboembolism: Does Low Dose Fit All?**
M. Biglietto, S. Sorella, L. V. Cappelli, B. Mandelli, D. Kasmi, E. Baldacci, A. Chistolini
- PO64 Management of Bleeding Risk in Patients with Hepatocellular Carcinoma Receiving Systemic Therapy: A survey of clinical practice**
T. Van Broeckhoven, E. Van Gansewinkel, J. De Bruijne, F. Eskens, D. De Groot, K. Hermans, N. Mohammad, F. Van Vilsteren, C. Verslype, W. Moris, M. Roest, B. De Laat, J. De Vos-Geelen, M. Kramer On Behalf Of The Dutch Hepatocellular & Cholangiocarcinoma Group
- PO65 Ovaric cancer presenting with cold-agglutinin mediated hemolytic anemia, pulmonary thromboembolism and deep vein thrombosis**
R. Cannas

PO66 Venous cancer-associated thrombosis: a systematic review and meta-analysis of sex-specific differences

A. M. Fioretti, M. Carrier, R. Farah, N. L. Bragazzi

Poster display only

PO67 Targeted therapies for cancer and the risk of Arterial and Venous Thromboembolism

O. Iqbal

PO68 Risk of venous thromboembolism in patients with cancer and migraine: A cohort analysis among Danish National Health Survey participants

O. Rosenkrantz, P. Szentkúti, L. Amdisen, E. Horváth-Puhó, A. L. Pedersen, H. E. Bøtker, H. Elser, J. P. Vandenbroucke, H. T. Sørensen

PO69 Incidental cancer detected during emergency diagnostic work-up for acute pulmonary embolism: a retrospective cohort study

L. Mocerino, A. Casoria, S. Mangiacapra, M. Amitrano, V. Bassi, A. Tufano

PO70 Hemostatic abnormalities in a patient with Waldenstrom's Macroglobulinemia

M. Gagliardi, L. Capone, A. Ciampa

PO71 A strange case of isolated distal deep vein thrombosis: not as benign as it may seem

M. Nunziata, F. Cannavacciuolo, V. Iorio, N. Iuliano, A. Casoria, V. Scarano, V. Di Fronzo, M. G. Montuori, A. Ciervo, R. Natale, L. Santarpia, M. Amitrano

PO72 Catheter-related thrombosis vs fibroblastic sleeve. Incidence and impact in oncological and hematological patients with peripherally inserted central catheter

M. Nunziata, S. Mangiacapra, F. P. Damiano, N. Iuliano, V. Iorio, R. Natale, L. Santarpia, M. Amitrano

PO73 Upper limb deep vein thrombosis, a retrospective observational study on a cohort of oncological patients

S. Mangiacapra, R. Natale, L. Santarpia, V. Iorio, N. Iuliano, A. Casoria, M. Nunziata, V. Di Fronzo, M. G. Montuori, M. Mastroianni, A. Ciervo, M. Amitrano

PO74 Prediction of brain cancer-associated thrombosis by imaging-based machine learning: Results from the Vienna Cancer and Thrombosis Study

T. Hoberstorfer, J. Hennenberg, C. Spielvogel, J. Furtner, C. Marosi, A. Berghoff, G. Kasprian, M. Preusser, I. Pabinger, C. Ay, J. Riedl